Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
AAV-hTERT by Libella Gene Therapeutics for Ageing: Likelihood of Approval
AAV-hTERT is under clinical development by Libella Gene Therapeutics and currently in Phase I for Ageing. According to GlobalData, Phase...
Data Insights
AAV-hTERT by Libella Gene Therapeutics for Critical Limb Ischemia: Likelihood of Approval
AAV-hTERT is under clinical development by Libella Gene Therapeutics and currently in Phase I for Critical Limb Ischemia. According to...